Igen (US) to launch Origen analyser in Japan:
This article was originally published in Clinica
Executive Summary
Igen (US) is to launch its Origen analyser in Japan following US release earlier this year. The company will work with Eisai to develop an Origen-based clinical diagnostic system in Japan, says Igen CEO and chairman Samuel Wohlstadter. Igen also has an agreement with Boehringer Mannheim, which owns a worldwide licence to use Igen's Origen-based technology to develop diagnostic instruments and assays. Boehringer hopes to launch an instrument, the prototype of which was shown at Medica in 1994, in Europe within a year and in Japan and the US soon after.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.